Allogeneic bone marrow transplantation in HIV people with hematological malignancies: Post-transplant cyclophosphamide to overcome the HLA-matching barrier.

Allogeneic bone marrow transplantation (allo-BMT) in people living with HIV (PLWH) is challenging because of concerns on infectious complications and interactions between antiretroviral therapy (ART) and immunosuppressive agents. Ambinder and colleagues performed the only one available prospective trial reporting 0% non-relapse mortality at 100-days in seventeen PLWH, who received allo-BMT from HLA-matched donors (7 matched-related donor, MRD; 10 matched-unrelated donor, MUD)1 .